Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Arkin Holdings raises $270 million for new biotech fund

From Calcalistech

By

September 1, 2025

Arkin Holdings raises $270 million for new biotech fund

Arkin Holdings, which manages $2 billion in assets, has raised $270 million for a new fund named Arkin Bio-Capital focused on biotechnology investments.

View original article on calcalistech.com

Most Recent

Founders Fund’s outlier bet on humanely killed fish

Founders Fund’s outlier bet on humanely killed fish

Shinkei makes a refrigerator-sized robot called Poseidon to kill fish quickly and humanely.

Jun 20, 2026

He made your free video player run smoothly. Now he’s doing that for robots.

He made your free video player run smoothly. Now he’s doing that for robots.

French serial entrepreneur and open-source legend Jean-Baptiste Kempf has been building Kyber, an infrastructure layer to control remote devices in real time.

Jun 19, 2026

AI inference startup Baseten reportedly raising $1.5B months after its last mega-round

AI inference startup Baseten reportedly raising $1.5B months after its last mega-round

Startup Baseten is reportedly close to finalizing a $1.5 billion round at a $13 billion as the “inference gold rush" marches on.

Jun 18, 2026

The 11 standout startups from YC’s Demo Day, according to VCs

The 11 standout startups from YC’s Demo Day, according to VCs

TechCrunch spoke to investors to find the hottest startups in the Spring 2026 YC batch. Some of them commanded valuations of over $175 million, VCs said.

Jun 18, 2026

Similar Posts

Acrew Capital hits five years, raises $700M

Acrew Capital hits five years, raises $700M

Acrew Capital has raised $700 million in fresh funds. The San Francisco-based venture capital firm announced in a blog post on Thursday that it raised $700 million to invest in companies building in data and security, healthcare, or fintech. This fundraise brings the firm’s assets under management to $1.7 billion. It’s unclear how much of the $700 million will go to the firm’s early-stage strategy, which invests $1 million to $15 million into seed and Series A companies, and how much will go fo

Oct 18, 2024

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners closed its second fund, raising $82 million. It hopes to invest in at least 25 early-stage companies, writing check sizes between $1 million and $2.3 million, with 50% of the fund reserved for follow-on investments.

May 29, 2025

Catalio Capital closes over $400M Fund IV

Catalio Capital closes over $400M Fund IV

Catalio Capital Management announced the closing of its more than $400 million Fund IV. The fund will continue the firm’s thesis of backing healthcare and biotechnology companies.

Jul 1, 2025

Arkin raises $100m for early-stage biotech fund

Arkin raises $100m for early-stage biotech fund

Jan 12, 2026

Most Recent

Founders Fund’s outlier bet on humanely killed fish

Founders Fund’s outlier bet on humanely killed fish

Shinkei makes a refrigerator-sized robot called Poseidon to kill fish quickly and humanely.

Jun 20, 2026

He made your free video player run smoothly. Now he’s doing that for robots.

He made your free video player run smoothly. Now he’s doing that for robots.

French serial entrepreneur and open-source legend Jean-Baptiste Kempf has been building Kyber, an infrastructure layer to control remote devices in real time.

Jun 19, 2026

AI inference startup Baseten reportedly raising $1.5B months after its last mega-round

AI inference startup Baseten reportedly raising $1.5B months after its last mega-round

Startup Baseten is reportedly close to finalizing a $1.5 billion round at a $13 billion as the “inference gold rush" marches on.

Jun 18, 2026

The 11 standout startups from YC’s Demo Day, according to VCs

The 11 standout startups from YC’s Demo Day, according to VCs

TechCrunch spoke to investors to find the hottest startups in the Spring 2026 YC batch. Some of them commanded valuations of over $175 million, VCs said.

Jun 18, 2026

Similar Posts

Acrew Capital hits five years, raises $700M

Acrew Capital hits five years, raises $700M

Acrew Capital has raised $700 million in fresh funds. The San Francisco-based venture capital firm announced in a blog post on Thursday that it raised $700 million to invest in companies building in data and security, healthcare, or fintech. This fundraise brings the firm’s assets under management to $1.7 billion. It’s unclear how much of the $700 million will go to the firm’s early-stage strategy, which invests $1 million to $15 million into seed and Series A companies, and how much will go fo

Oct 18, 2024

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners closed its second fund, raising $82 million. It hopes to invest in at least 25 early-stage companies, writing check sizes between $1 million and $2.3 million, with 50% of the fund reserved for follow-on investments.

May 29, 2025

Catalio Capital closes over $400M Fund IV

Catalio Capital closes over $400M Fund IV

Catalio Capital Management announced the closing of its more than $400 million Fund IV. The fund will continue the firm’s thesis of backing healthcare and biotechnology companies.

Jul 1, 2025

Arkin raises $100m for early-stage biotech fund

Arkin raises $100m for early-stage biotech fund

Jan 12, 2026